Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 137 Carcinoma, Non-Small-Cell Lung 38 Carcinoma, Renal Cell 33 Neoplasm Metastasis 32 Prostatic Neoplasms 22 Brain Neoplasms 21 Lung Neoplasms 20 Pancreatic Neoplasms 19 Uveal Melanoma 17 Neoplasms 17 Carcinoma, Hepatocellular 13 Breast Neoplasms 13 Sarcoma 12 Skin Neoplasms 10 Kidney Neoplasms 10 Urinary Bladder Neoplasms 9 Squamous Cell Carcinoma of Head and Neck 9 Glioblastoma 9 Triple Negative Breast Neoplasms 8 Ovarian Neoplasms 8 Colorectal Neoplasms 8 Carcinoma, Transitional Cell 8 Small Cell Lung Carcinoma 7 Multiple Myeloma 7 Colonic Neoplasms 7 Clear-cell metastatic renal cell carcinoma 7 Recurrence 6 Myelodysplastic Syndromes 6 Diabetes Mellitus, Insulin-Dependent, 12 6 Uterine Cervical Neoplasms 5

Interventions

Radiotherapy 4 Immune Checkpoint Inhibitors 4 Oxaliplatin 1 Nivolumab 1 Ipilimumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Advanced NSCLC × Ipilimumab × Clear all

NCT04043195 2025-05-28

NSCLC

University of California, San Diego

Phase 1/2 Active not recruiting

Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡